top of page

The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database

blonca9
Mar 17
1 min read

CEO Nima Alidoust and CSO Johnny Yu describe Vevo's contribution of 100M cells, plus a 60,000 drug-patient interaction map, that has been combined with Arc's 200M cell gene expression data from 21 different species (scBaseCamp). They explain the size and scale of this now open source atlas, and the potential utility of it to outside researchers.

Recent Posts

See All

Dianthus Therapeutics made waves in September when it announced data from its lead program claseprubart in generalized Myasthenia Gravis - CEO Marino Garcia walks us through the program and data

OrbiMed's Carl Gordon shares his take on biotech's 2025 and what could be ahead for the sector in 2026

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate